Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus reduced-dose ipilimumab in unresectable metastatic melanoma
2016-000742-61Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoints: Overall response rate and Duration of response. Started Jan 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-000742-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000742-61.